Journal article
In-vitro Activity of Avermectins against Mycobacterium ulcerans
TF Omansen, JL Porter, PDR Johnson, TS van der Werf, Y Stienstra, TP Stinear
Plos Neglected Tropical Diseases | PUBLIC LIBRARY SCIENCE | Published : 2015
Abstract
Mycobacterium ulcerans causes Buruli ulcer (BU), a debilitating infection of subcutaneous tissue. There is a WHO-recommended antibiotic treatment requiring an 8-week course of streptomycin and rifampicin. This regime has revolutionized the treatment of BU but there are problems that include reliance on daily streptomycin injections and side effects such as ototoxicity. Trials of all-oral treatments for BU show promise but additional drug combinations that make BU treatment safer and shorter would be welcome. Following on from reports that avermectins have activity against Mycobacterium tuberculosis, we tested the in-vitro efficacy of ivermectin and moxidectin on M. ulcerans. We observed mini..
View full abstractRelated Projects (1)
Grants
Awarded by National Science Foundation
Funding Acknowledgements
TPS was supported by a Fellowship from the National Health and Medical Research Council of Australia (GNT1008549, www.nhmrc.gov.au). TFO was supported by the Buruli ulcer Groningen foundation (https://buruli1ulcer2groningen3.wordpress.com/2014/01/26/buruli-ulcer-groningen/). YS was supported by the Netherlands Organisation for Scientific Research (91610074, VENI grant, www.nwo.nl/en/funding). The funders had no role in study design, data collection and analysis, decision to publish or preparations of the manuscript.